HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

GSK plc (NYSE: GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

The Supreme Court on Friday rejected a challenge to the structure of a Department of Health and Human Services task force ...

The Charleston Area Medical Center (CAMC) Ryan White Program held an event Friday at three Walgreens Pharmacy locations ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

From the first reported case of AIDS to the present, what is the history of HIV-AIDS and are there parallels to the COVID-19 pandemic?

The task force that mandated preventive HIV drug coverage, which self-insured Christian employer said made it "complicit in ...

Raised by his aunt after the death of his parents, Nkumbu recalls her heartbreak the day he was suspended from school for ...

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

Matthew Hartle, Aliveness Project Medical Director, joined Amy Hockert on FOX 9's All Day on Thursday to talk about a new HIV prevention drug being offered.